Coya Therapeutics (NASDAQ:COYA) Given “Buy” Rating at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a report released on Tuesday,Benzinga reports. They currently have a $15.00 target price on the stock.

Several other brokerages also recently issued reports on COYA. Chardan Capital reissued a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a report on Thursday, November 7th. HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Coya Therapeutics in a research report on Monday, November 11th.

Coya Therapeutics Trading Up 5.2 %

COYA stock opened at $5.66 on Tuesday. The stock’s 50 day simple moving average is $5.95 and its 200 day simple moving average is $6.48. Coya Therapeutics has a 12-month low of $4.75 and a 12-month high of $10.69. The firm has a market cap of $94.58 million, a P/E ratio of -8.71 and a beta of 0.46.

Coya Therapeutics (NASDAQ:COYA) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.15. On average, research analysts forecast that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Insider Activity at Coya Therapeutics

In other news, CEO Arun Swaminathan purchased 5,000 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was purchased at an average cost of $7.34 per share, with a total value of $36,700.00. Following the purchase, the chief executive officer now owns 5,000 shares in the company, valued at $36,700. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders purchased 9,510 shares of company stock worth $69,615 in the last 90 days. Corporate insiders own 9.80% of the company’s stock.

Institutional Trading of Coya Therapeutics

Several institutional investors have recently modified their holdings of the company. Geode Capital Management LLC boosted its holdings in Coya Therapeutics by 3.3% during the third quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock worth $918,000 after buying an additional 4,485 shares in the last quarter. GHP Investment Advisors Inc. acquired a new stake in shares of Coya Therapeutics during the 3rd quarter valued at $169,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Coya Therapeutics during the 2nd quarter worth $101,000. Institutional investors and hedge funds own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.